Statins and Type 2 Diabetes Mellitus: An Update After 1 Year

Title:Statins and Type 2 Diabetes Mellitus: An Update After 1 Year

Volume: 22 Issue: 18

Author(s): Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis

Affiliation:

Keywords: IMPROVE-IT, diabetes mellitus, cancer, statins, new onset diabetes, ezetimibe.

Abstract: In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data.

Cite this article as:

Katsiki Niki, G. Athyros Vasilios, Karagiannis Asterios and P. Mikhailidis Dimitri, Statins and Type 2 Diabetes Mellitus: An Update After 1 Year, Current Pharmaceutical Design 2016; 22 (18) . https://dx.doi.org/10.2174/1381612822666160125114626